•
AP
APLS
Apellis Pharmaceuticals, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
2.65B
Volume
3.75M
52W High
$31.17
52W Low
$16.10
Open
$0.00
Prev Close
$20.47
Day Range
0.00 - 0.00
About Apellis Pharmaceuticals, Inc. Common Stock
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Latest News
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday?
Benzinga•Jan 13
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.•Jan 12
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight
GlobeNewswire Inc.•Dec 1
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
GlobeNewswire Inc.•Nov 5
Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsight
GlobeNewswire Inc.•Oct 22
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
GlobeNewswire Inc.•Oct 20
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•Aug 27
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
GlobeNewswire Inc.•Jul 28